# NCT03907488 (NCT03907488)

> Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03907488
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma
- Interventions: Biospecimen Collection; Brentuximab Vedotin; Computed Tomography; Dacarbazine; Doxorubicin Hydrochloride; Filgrastim; Magnetic Resonance Imaging; Nivolumab; Pegfilgrastim; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Vinblastine Sulfate
- Enrollment: 994
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 131
- YouTube: 48
- Podcasts: 34
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03907488

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03907488", "email": "<work email>"}; the inbox owner confirms by the emailed link.